P-290 Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel

thrombopoietic growth factors and platelet transfusion.Conclusions: We analyzed the factors affecting thrombocytopenia in RRMM patients after anti BCMA CAR -T treatment and developed for the first time a predictive model for prolonged thrombocytopenia recovery.Prolonged thrombocytopenia may occur in patients with low bone marrow reserve and high tumor burden.